These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17566847)

  • 1. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
    Kanai M; Matsumoto S; Nishimura T; Shimada Y; Watanabe G; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Teramukai S; Mitsumori M; Chiba T; Sakai Y; Fukushima M
    Int J Clin Oncol; 2007 Jun; 12(3):224-7. PubMed ID: 17566847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
    Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
    Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].
    Irino T; Egawa T; Kenmochi T; Ito Y; Mihara K; Okamura A; Eto E; Inaba Y; Murakawa M; Nagashima A
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2401-4. PubMed ID: 22202395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
    Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
    Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
    Osaka Y; Takagi Y; Hoshino S; Tachibana S; Tsuchida A; Aoki T
    Dis Esophagus; 2006; 19(6):473-6. PubMed ID: 17069591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer].
    Funaki H; Miura S; Morioka E; Kaida D; Ohnishi T; Ohno Y; Tomita Y; Noguchi M; Fujita H; Kinami S; Nakano Y; Ueda N; Kosaka T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2384-6. PubMed ID: 25731531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
    Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
    Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
    Kawada J; Iwase K; Deguchi K; Higashi S; Deguchi T; Matsuda C; Tamagawa H; Omori K; Nishikawa K; Nomura M; Takagi M; Fukui A; Tanaka Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2095-7. PubMed ID: 23267988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T; Sakayori M; Kato S; Chiba N; Miyazaki S; Nemoto K; Shibata H; Shimodaira H; Ohtsuka K; Kakudo Y; Sakata Y; Ishioka C
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
    Matsumoto H; Hirabayashi Y; Kubota H; Murakami H; Higashida M; Haruma K; Hiratsuka J; Nakamura M; Hirai T
    Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
    Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
    Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
    Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
    Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma.
    Peng PJ; Lv BJ; Tang C; Liao H; Lin Z; Liu YM; Wang ZH; Wang SY; Cheng ZB
    Drug Des Devel Ther; 2015; 9():6401-5. PubMed ID: 26677316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.